* April 1, 2010 - Vaccine with no jab: Protein
vaccines for needle-free immunization through the skin - Most immunizations
currently involve an injection in the arm. In the future, vaccination may be
accomplished without the unpleasant jab of a needle: a team led by Victor C.
Yang at the University of Michigan (USA) has developed a method by which
vaccines can pass directly through the skin without a needle. As the researchers
report in the journal Angewandte Chemie, merely linking a special short peptide
molecule to the vaccine, which can then be administered in the form of
a patch, will do the job. - PhysOrg.com
April 24, 2010
- AFFiRiS'
AD02
Alzheimer's vaccine candidate in phase II clinical testing -
AFFiRiS AG via News-Medical.Net
April 22, 2010 - IAVI
and Lentigen to Collaborate on Design of Novel AIDS Vaccine Candidate -
press release - Lentigen Corporation via PRNewswire - "Lentigen's technology
relies on a synthetic version of a virus related to HIV that has been
engineered, along with other safety modifications, to be incapable of inserting
itself into the human genome."
April 22, 2010 - Liquidia
closes $25M Series C to fund vaccine delivery tech - FierceVaccines -
"Liquidia, which is based in Research Triangle Park, NC, uses its PRINT
technology to create nanoparticles that can be used to more precisely deliver
vaccine payloads, improving the safety and efficacy of the jab."
April
21, 2010 - Potent
Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided
Micro-Targeted Skin Delivery in a Mouse Model - journal article (PLoS One) - "Here we show that the Nanopatches
deliver a seasonal influenza vaccine (Fluvax® 2008) to directly contact
thousands of APCs, in excellent agreement with theoretical prediction. By
physically targeting vaccine directly to these cells we induced protective
levels of functional antibody responses in mice and also protection against an
influenza virus challenge that are comparable to the vaccine delivered
intramuscularly with the needle and syringe—but with less than 1/100th of the
delivered antigen."
April 21, 2010 - ImmunoCellular
Therapeutics Enters into Research Agreement with University of Pennsylvania to
Support Phase II Clinical Trial of ICT-107 - ImmunoCellular Therapeutics via
Business Wire via MarketWatch - "ICT-107 is a dendritic-cell based vaccine that
works by activating a patient's immune system against specific tumor-associated
antigens. This is accomplished by extracting dendritic cells from a patient,
loading them with the antigens, and reintroducing them to the patient's body to
trigger an immune response."
April 19, 2010 - NanoBio To
Develop Vaccine For Treatment Of Hepatitis B - NanoBio Corporation via
Michigan Technology News - "Michigan Nanotechnology Institute for Medicine and
Biological Sciences received funding through a Phase 1 Technology Transfer award
by the National Institutes of Health (NIH), to evaluate a potential therapeutic
intranasal vaccine for the treatment of hepatitis B in patients."
April 19, 2010 - Vaccine For
Urinary Tract Infections - TheDenverChannel.com
April 18, 2010 - Protein
Potential LLC Awarded $3 Million U.S. NIH Phase II Small Business Innovation
Research Grant to Develop a Vaccine Targeting Plasmodium vivax, a Neglected
Cause of Malaria - Protein Potential LLC via PRNewswire via News
Blaze
May 15, 2010 - \Update on
Research and Development Pipeline: Tuberculosis Vaccines - journal
article (Clinical Infectious
Diseases)
April 26, 2010 - An
inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA
system - journal article (Vaccine)
April 26, 2010 - Trivalent
Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high
level of humoral immunity but also induce immune interference among component
types - journal article (Vaccine)
April 14, 2010 - Aeras
and Crucell Announce Start of Phase II TB study in South Africa - Crucell
and Aeras via Marketwire via COMTEX via MarketWatch - "Dutch biopharmaceutical
company Crucell N.V. /quotes/comstock/15*!crxl/quotes/nls/crxl (CRXL 20.53,
+0.14, +0.69%) (SWISS: CRX) and the Aeras Global TB Vaccine Foundation today
announced the start of a Phase II clinical trial of the jointly developed
tuberculosis (TB) vaccine candidate AERAS-402/Crucell Ad35 in HIV infected
adults. The Phase II study is designed to test the safety and efficacy of
AERAS-402/Crucell Ad35 in adults infected with HIV and will be conducted by the
Aurum Institute in Klerksdorp, South Africa. All Aeras-sponsored TB vaccine
candidates have been or will be tested for safety in people living with
HIV."
April 13, 2010 - Oral
Vaccine May Reduce Exacerbations in Patients With COPD - A novel vaccine may
help reduce the number and severity of exacerbations in patients with severe
chronic obstructive pulmonary disease (COPD). - American College of Chest
Physicians via ScienceDaily
April 12, 2010 - Sanofi Pasteur
ties up with US NMRC to develop travelers diarrhea vax - BioSpectrum - "The
core ETEC adhesin vaccine technology, developed by NMRC, was exclusively
licensed to Sanofi Pasteur, along with a second technology that efficiently
packages the adhesin with a toxoid vaccine component, co-developed by NMRC and
the University of Colorado Denver."
March 23, 2010 - Title:
Generation of virus-like particles and use as panfilovirus vaccinewww.pharmcast.com
Patent
application title: DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH
INFLUENZA VACCINES - Inventors: Jens-Peter Gregersen - Agents: NOVARTIS
VACCINES AND DIAGNOSTICS INC. - Assignees: CHIRON BEHRING GMBH & CO. - www.faqs.org
Novartis
Vaccines And Diagnostics Inc. patents - The following is a sampling of
recent Novartis Vaccines And Diagnostics Inc. patent applications (USPTO Patent
Application #, Patent Title) sorted by month. - FreshPatents.com
April
2010 - Enhancing DNA
vaccine potency by co-administration of xenogenic MHC class-I DNA -
journal article (Gene
Therapy)
April 2010 - Vaccination
with a potent DNA vaccine targeting B-cell epitopes of hGRP induces prophylactic
and therapeutic antitumor activity in vivo - journal article (Gene Therapy)
April 6, 2010 - MOLOGEN
AG receives funding to develop a DNA vaccine against hepatitis B - The DNA
specialists from Berlin are intensifying their work on developing innovative and
improved DNA-based vaccines. This is a response to a high demand - with an
interesting market potential - PipelineReview.com
April 2010 - Randomized Trial on the
Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational
Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly
with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in
Adolescents and Young Adults - journal article (Clinical and Vaccine Immunology)
April
7, 2010 - Cancer
vaccines may be on the verge of wider use - Pittsburgh Post-Gazette - "The
encouraging results of MUC1 vaccines aren't confined to animals. The version
that is now being tested by Merck showed a 17-month survival advantage for
advanced lung cancer patients who got the vaccine vs. those who didn't in an
earlier trial. While the current testing has been suspended temporarily because
one patient got encephalitis, the man whose company invented the vaccine is
encouraged by the progress it has made. Robert Kirkman, president of
Oncothyreon, the Seattle, Wash., company that developed the vaccine, said he
understands the logic of testing cancer vaccines on patients who aren't as sick,
but said that presents a financial challenge. If vaccines were to be tested on a
large group of patients with earlier stage cancer, it could mean following them
for up to 10 years to see if the therapy was effective, and that would be
enormously expensive."
April 7, 2010 - iBio
Announces Rights Grant for Anthrax-Plague Combination Vaccine - Business
Wire via MarketWatch - "iBio and CMB have developed a new biologics production
platform based on the use of green plants to manufacture vaccines and
therapeutic proteins. The technology has been successfully applied to a variety
of candidate products, including an avian influenza vaccine planned to be the
first product to enter a human clinical trial in 2010."
April 6, 2010 -
Oral
Vaccine May Reduce Exacerbations in Patients With COPD - American College of
Chest Physicians via Doctor's Guide - "Maharaj
Kishore Tandon, MD, Hollywood Private Hospital, Perth, Western Australia, and
colleagues developed a new oral immunotherapy (HI-164OV) using Haemophilus
influenzae."
April 6, 2010 - Netherlands
Vaccine Institute, PharmaJet Collaborate For Needle-free Delivery -
Netherlands Vaccine Institute (NVI) and PharmaJet have entered into a
collaboration to evaluate PharmaJet's intra-dermal needle-free delivery
technology with NVI's Salk inactivated polio vaccine (IPV). - Pharmaceutical
Business Review
April 6, 2010 - Crucell
Announces Collaboration with GlaxoSmithKline Biologicals on Second Generation
Malaria Vaccine Candidate - Crucell via Marketwire via CNN Money - "Under
the terms of the letter of agreement, Crucell will contribute its recombinant
malaria vaccine candidate, Ad35-CS, based on Crucell's AdVac® technology and
PER.C6® manufacturing platform and GSK will contribute its late stage malaria
vaccine candidate RTS,S/AS. Financial details of the agreement were not
disclosed."
April 1, 2010 - Notice:
Prospective Grant of Exclusive License: Development of PANVAC and Tumor
Associated Antigens as Cancer Vaccines - National Institutes of
Health, Public Health Service, HHS via www.pharmcast.com - "The patent rights in
these inventions have been assigned to the United States of America. The
prospective exclusive license territory may be worldwide and the field of use
may be use of Licensed Patent Rights for development of therapeutics for human
cancers. The field of use will specifically exclude prostate cancer, melanoma
and colorectal cancer. For the avoidance of doubt, delivery formulations shall
specifically exclude canary poxvirus vectors, NYVAC, non-viral eukaryotic
expression vectors and recombinant yeast vectors in all geographic
territories."
April 4, 2010 - Scientists at Gorlaeus
Laboratories report research in atherosclerosis vaccines - Cardiovascular Research via NewsRx
May
1, 2010 - Effect of
Vaccination with Modified Vaccinia Ankara (ACAM3000) on Subsequent Challenge
with Dryvax - journal article (The
Journal of Infectious Diseases)
* May 1, 2010 - Randomized
Controlled Clinical Trial of Fractional Doses of Inactivated Poliovirus Vaccine
Administered Intradermally by Needle‐Free Device in Cuba - journal
article (The Journal of Infectious
Diseases)
(patent) - The United States of America as represented by the Secretary of the
Army (Washington, DC) via
* April 1, 2010 - Vaccine with no jab: Protein
vaccines for needle-free immunization through the skin - Most immunizations
currently involve an injection in the arm. In the future, vaccination may be
accomplished without the unpleasant jab of a needle: a team led by Victor C.
Yang at the University of Michigan (USA) has developed a method by which
vaccines can pass directly through the skin without a needle. As the researchers
report in the journal Angewandte Chemie, merely linking a special short peptide
molecule to the vaccine, which can then be administered in the form of a patch,
will do the job. - PhysOrg.com
linking a special short peptide
molecule to the vaccine, which can then be administered in the form of a patch,
will do the job. - PhysOrg.com
